

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :	Mizhou Hui	Art Unit :	1646
Serial No. :	10/576,995	Examiner :	Landsman, Robert S
Filed :	October 4, 2006	Conf. No. :	7230
Title :	A Novel Chimeric Polypeptide And Use Thereof		

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF REFERENCE

For the sake of a complete record, Applicant submits herewith a Chinese-language reference, CN1465597A. Also enclosed is an English translation of the title and abstract of this reference. The reference was published on January 7, 2004, which is after the priority date of this application, i.e., August 26, 2003. Thus, the reference does not qualify as prior art.

No fee is believed to be due. Please apply any other charges or credits to Deposit Account No. 50-4189, referencing Attorney Docket No. 50046-003US1.

Respectfully submitted,

Date: _____

9-25-2009

Jianming Hao, Ph.D.
Reg. No. 54,694

Customer No. 69713
Occhiuti Rohlicek & Tsao LLP
10 Fawcett Street
Cambridge, MA 02138
Telephone: (617) 500-2512
Facsimile: (617) 500-2499
84832.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :	Mizhou Hui	Art Unit :	1646
Serial No. :	10/576,995	Examiner :	Landsman, Robert S
Filed :	October 4, 2006	Conf. No. :	7230
Title :	A Novel Chimeric Polypeptide And Use Thereof		

ENGLISH TRANSLATION OF THE TITLE AND ABSTRACT OF CN1465597A

Title:

A fusion protein comprising a soluble TNF II receptor and an interleukin I receptor antagonist (IL1Ra), a method of producing the fusion protein, and a pharmaceutical composition.

Abstract:

This invention relates to a fusion protein comprising a soluble TNF II receptor, p75, and an interleukin I receptor antagonist, IL1Ra; a nucleic acid sequence encoding the fusion protein; a method of producing the fusion protein; and a pharmaceutical composition comprising the fusion protein.